NRX Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by NRX Pharmaceuticals, Inc. on March 3, 2023, reporting events occurring on the same date. The company is incorporated in Delaware and its common stock (NRXP) and warrants (NRXPW) trade on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance and voting results.
Material Changes and Events
On March 3, 2023, the Company reconvened a special meeting of stockholders where a quorum was present. Stockholders approved Proposal 1 regarding the issuance of shares of common stock to Streeterville Capital, LLC in accordance with Nasdaq Listing Rule 5635(d).
Voting Results
| Vote Category | Number of Votes |
|---|---|
| Votes For | 38,338,555 |
| Votes Against | 311,870 |
| Abstentions | 373,843 |
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, or contingencies beyond the approval of the stock issuance.
Key Facts for Investor Verification
- Stockholders approved the issuance of common stock to Streeterville Capital, LLC.
- The issuance was conducted to comply with Nasdaq Listing Rule 5635(d).
- The proposal passed with approximately 99.2% of votes cast in favor.
- No financial performance data is included in this specific filing.